🇮🇪 Jazz Pharmaceuticals plc
Forum topic · JAZZ · Company page: financials, ownership and filings
Join the discussion on Jazz Pharmaceuticals plc
Loading…
Results announced on 2 November 2026
Jazz Pharmaceuticals plc announced results on 2 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $1.2 billion (up 10% from a year earlier) and a net loss of $483 million.
Insider trading in October 2026
Directors and officers of Jazz Pharmaceuticals plc reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $1,854,780 in 2 trades.
Awards, option exercises and shares withheld for tax are not counted.
Results announced on 26 October 2026
Jazz Pharmaceuticals plc announced results on 26 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $1.2 billion (up 10% from a year earlier) and a net loss of $483 million.
Mutual funds: 508 funds hold $7.4 billion
508 mutual funds in 2 countries hold shares of Jazz Pharmaceuticals plc worth $7.4 billion, about 47.6% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 245 funds added shares and 176 sold; on balance they bought $684 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.